Premium
COMBINATION OF IRAK4 (CA‐4948) AND BTK (VECABRUTINIB) INHIBITORS SHOW SUPERIOR EFFICACY IN PRECLINICAL MODELS OF ABC DLBCL TUMORS CONTAINING MYD88 ‐L265P MUTATIONS
Author(s) -
Booher R.N.,
Borek M.,
DellaRocca S.,
Samson M.S.,
Fox J.A.,
Taverna P.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.195_2631
Subject(s) - ibrutinib , bruton's tyrosine kinase , cancer research , breakpoint cluster region , b cell , signal transduction , diffuse large b cell lymphoma , b cell receptor , in vivo , lymphoma , biology , immunology , chronic lymphocytic leukemia , receptor , tyrosine kinase , microbiology and biotechnology , leukemia , genetics , antibody